Clinical trial
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
NCT05161429 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- July 1, 2021
- Completion date
- June 30, 2024
- Enrollment
- Not reported
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.